Certara Announces Release of Simcyp™ Simulator Version 21, Expanding Capabilities to Align with Recent Regulatory Guidances

Simcyp Simulator has been used to inform more than 250 label claims for 85+ novel drugs PRINCETON, N.J.— December 2, 2021 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the release of Simcyp Simulator Version 21, which updates the Company’s population-based modeling and simulation platform. The Simcyp Simulator is used throughout … Continued

Certara Announces Update of D360™ Scientific Informatics Software

New capabilities increase efficiency in analyzing and developing small molecules and biologic drugs Princeton, N.J., November 29, 2021: Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the release of D360 version 21.5, an industry-leading scientific informatics software for discovery scientists to integrate many data sources and analyze small molecules and biologic drugs … Continued

Certara Announces Closing of Public Offering of Common Stock

PRINCETON, N.J.—November 22, 2021– Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the closing of its underwritten public offering of 10,000,000 shares of its common stock by certain existing stockholders at a public offering price of $31.00 per share. The selling stockholders have granted the underwriters a 30-day option to purchase up … Continued

Certara Announces Pricing of Public Offering of Common Stock

PRINCETON, N.J., November 17, 2021. — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the pricing of its underwritten public offering of 10 million shares of its common stock by certain existing stockholders (the “selling stockholders”) at a price to the public of $31.00 per share. Additionally, the selling stockholders have granted the underwriters … Continued

Certara Announces Proposed Public Offering of Common Stock

PRINCETON, N.J.– November 15, 2021– Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced a proposed underwritten public offering by certain selling stockholders of 10 million shares of its common stock pursuant to a registration statement filed with the Securities and Exchange Commission. Additionally, the selling stockholders intend to grant the underwriters a … Continued

Certara Reports Third Quarter 2021 Financial Results

Raises full year 2021 guidance, reflecting strong revenue growth and the acquisition of Pinnacle 21 PRINCETON, N.J.—November 9, 2021– Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the third quarter of fiscal year 2021. Highlights: Revenue was $73.9 million, compared to $60.3 million in the third quarter of … Continued

Certara Appoints James E. Cashman III as Chairman of Board of Directors

High-tech CEO with decades of experience supports continued innovation and growth Princeton, N.J., November 8, 2021 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that James E. Cashman III, a current Board member, will be appointed Chairman of the Board of Directors, effective as of December 1, 2021.  Jim succeeds Sherilyn … Continued

Certara to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference

PRINCETON, N.J.— November 3, 2021 — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that William F. Feehery, Chief Executive Officer, and Andrew Schemick, Chief Financial Officer will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference. A webcast of the fireside chat will be available beginning … Continued

Pinnacle 21 Awarded FDA Contract for 5 Years for Software and Services

Pinnacle 21 Enterprise software expedites regulatory review of all study submission data Princeton, N.J., October 28, 2021 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has awarded a five-year contract with Pinnacle 21 for ongoing software and related services support for the agency’s DataFit … Continued

Certara’s Simcyp™ COVID-19 Vaccine Model Wins R&D 100 Award

Biosimulation tool to conduct ‘what-if’ scenarios with virtual patients recognized in Software/Services category PRINCETON, NJ – October 25, 2021 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that its Simcyp COVID-19 Vaccine Model has won an R&D 100 Award, which recognizes the top 100 “R&D pioneers and their revolutionary ideas in … Continued

1 of 28
Back to top
Powered by Translations.com GlobalLink OneLink Software